135271-49-7

Basic information

• Product Name: (R)-Salmeterol 1-hydroxy-2-naphthoic acid salt
• Synonyms: (R)-Salmeterol 1-hydroxy-2-naphthoic acid salt;1,3-Benzenedimethanol, 4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (a1R)-, 1-hydroxy-2-naphthalenecarboxylate (salt) (9CI);2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with (a1R)-4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (1:1) (9CI)
• CAS NO: 135271-49-7
• Molecular Formula: C36H45NO7
• Molecular Weight: 603.76
• Mol File: 135271-49-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-Salmeterol 1-hydroxy-2-naphthoic acid salt(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-Salmeterol 1-hydroxy-2-naphthoic acid salt(135271-49-7)
• EPA Substance Registry System: (R)-Salmeterol 1-hydroxy-2-naphthoic acid salt(135271-49-7)

Safety Data

• Hazardous Substances Data: 135271-49-7(Hazardous Substances Data)

Usage

General Description

(R)-Salmeterol 1-hydroxy-2-naphthoic acid salt is a chemical salt form of (R)-salmeterol, a long-acting beta2-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). This salt form is created by combining (R)-salmeterol with 1-hydroxy-2-naphthoic acid, resulting in a more stable, water-soluble form of the drug. (R)-Salmeterol works by relaxing the smooth muscles in the airways, allowing for easier breathing and reducing symptoms of asthma and COPD. Additionally, the 1-hydroxy-2-naphthoic acid salt form of (R)-salmeterol may have improved pharmacokinetic properties and stability compared to the free base form, making it a potentially more effective and convenient treatment option for patients with respiratory conditions.

Upstream product

• 934842-69-0 4-hydroxy-1-[[[6-(4-phenylbutoxy)hexyl](phenylmethyl)amino]methyl]-1,3-benzenedimethanol 
• 163923-19-1 2-hydroxy-5-<<<6,6-(4-phenylbutoxy)hexylbenzyl>amino>acetyl>benzaldehyde 
• 115787-50-3 5-(2-bromoacetyl)-2-hydroxybenzaldehyde 
• 97664-55-6 N-[6-(4-phenylbutoxy)hexyl]benzenemethanamine 
• 89365-50-4 salmeterol 

Relevant articles and documents

Control of the physical form of salmeterol xinafoate

Two approaches to the generation of particles of the phenethanolamine, salmeterol xinafoate, are discussed. To produce particles with good flow properties a fast cooling crystallisation process was developed which delivered salmeterol xinafoate as spherical agglomerates of microcrystals which had good powder flow characteristics and could be micronised efficiently in a fluid energy mill. In a radically different approach, salmeterol xinafoate was crystallised using supercritical carbon dioxide in the SEDS (solution enhanced dispersion by supercritical fluids) process. By means of this technique the solid state form, crystal habit, and particle size of salmeterol xinafoate could be effectively controlled.

PROCESS FOR THE PREPARATION OF SALMETEROL XINAFOATE

The present invention relates to an improved process for the preparation of Salmeterol Xinafoate of Formula (I).

SUBSTITUTED ETHANOLAMINES

The present invention relates to new substituted ethanolamine adrenergic receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.